A recent study on uterine sarcomas was performed, showing that potentially actionable mutations were identified in nearly half of the analyzed patients, even if the study confirmed the recurrent mutational profile of uLMS dictated by TP53, RB1 and ATRX genetic hits [19]. The gene discussed is TP53; the disease is uterine corpus sarcoma.